Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia

Medical and Pediatric Oncology
J BoosH Jürgens

Abstract

The importance of the cellular pharmacokinetics of cytarabine triphosphate (ara-CTP) with regard to therapeutic efficacy is well established. In vitro and in vivo monitoring of pharmacokinetic parameters of leukemic blast cells were initiated in order to contribute to the pharmacological basis of optimal ara-C treatment strategies. Peripheral or bone marrow blast cells from 66 leukemic patients [51 acute myelogenous leukemia (ALL), 15 acute lymphoblastic leukemia (AML) were separated and incubated with ara-C for 1 hour and in ara-C-free medium for another 3 hours, and the intracellular formation and retention of ara-CTP was measured. In eight children who received continuous ara-C infusion for induction treatment, the ara-CTP concentration in circulating blast cells was monitored in vivo. The in vitro values observed in this assay corresponded to the cellular levels monitored in vivo. The ara-CTP retention differed clearly among the individual groups, as classified by immunophenotype at the time of the initial diagnosis: non-T-ALL 67+/-25% (x+/-SD, n=33), T-ALL 37+/-15% (n=8), and AML 34+/-18% (n=14). The difference in ara-CTP retention between non-T-All and AML (P<0.05) as well as T-ALL (P<0.05) was significant. There was a te...Continue Reading

References

Jan 1, 1990·Journal of Cancer Research and Clinical Oncology·J RitterG Schellong
Jan 1, 1990·Haematology and Blood Transfusion·H RiehmG Schellong
Jan 1, 1989·Advances in Experimental Medicine and Biology·H KawasakiM Sakurai
May 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V HeinemannW Plunkett
Feb 1, 1987·The Journal of Clinical Investigation·J C WhiteR L Capizzi
Sep 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L SlevinT A Lister
Feb 1, 1982·The Journal of Clinical Investigation·J S WileyA R Paterson
Feb 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U CreutzigG Schellong

❮ Previous
Next ❯

Citations

Jan 6, 2004·International Journal of Hematology·R Pieters, M L den Boer
Apr 6, 1999·British Journal of Clinical Pharmacology·L Lennard
May 9, 2003·Cancer Chemotherapy and Pharmacology·S A Flanagan, K A Meckling
Jan 1, 1997·Critical Reviews in Oncology/hematology·R PietersA J Veerman
Nov 3, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A FreundA Gescher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.